Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2015

Statin Pretreatment Prior to PCI: Are the Effects Real?

Presenter: Frederick Feit, C. Michael Gibson, Germano Di Sciascio

October 15, 2015

Presentation TCT 2015

Cilostazol: When to Consider (and Is the Data Robust?)

Presenter: Frederick Feit, C. Michael Gibson

October 15, 2015

Presentation TCT 2015

The PCSK9 Inhibitor Revolution

Presenter: Frederick Feit, C. Michael Gibson, Norman E. Lepor

October 15, 2015

Presentation TCT 2015

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Presenter: George D. Dangas, Paul A. Gurbel, Joshua W. Knowles

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

Presenter: Bernard J. Gersh, Stephen D. Wiviott

October 13, 2015

Presentation TCT 2015

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Evan A. Stein

October 13, 2015

Presentation TCT 2015

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Presenter: Bernard J. Gersh, Stephen D. Wiviott, David J. Maron

October 13, 2015

Presentation TCT 2015

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

Presenter: Gregg W. Stone, Renu Virmani, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Presentation TCT 2014

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Presenter: Valentin Fuster, Patrick W. Serruys, Harvey D. White

September 14, 2014

News Conference News TCT 2014

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

September 14, 2014

Presentation TCT 2013

PCSK9 Inhibitors: Too Good to Be True?

Presenter: Evan Stein

October 30, 2013

Presentation TCT 2012

PCSK9 Inhibitors: The Holy Grail?

Presenter: Evan Stein

October 23, 2012

Presentation TCT 2012

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Presenter: Elizabeth Jackson

October 23, 2012

Advertisement

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Statin Pretreatment Prior to PCI: Are the Effects Real?

Cilostazol: When to Consider (and Is the Data Robust?)

The PCSK9 Inhibitor Revolution

Hyperlipidemic Therapy: From Statins to PCSK9 Inhibitors

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Non-LDL Lowering Agents: Trials and Tribulations of HDL, Triglycerides, and Lp-PLA2 What Hasnt Worked, and Why?

PCSK9: Effects on LDL and Emerging Data on Cardiovascular Events

Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic?

Will PCSK9 Inhibitors Transform the Natural History of Atherosclerosis?

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

PCSK9 Inhibitors: Too Good to Be True?

PCSK9 Inhibitors: The Holy Grail?

Late Breaking Clinical Trials: STAMPEDE (Bariatric Surgery) and PCSK9 (LDL Reduction)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content